2026

Revised: July 16, 2026

The Future of Heart Disease Management

How to Use This Article

Medical disclaimer: This article is for education only and is not medical advice. Always consult your clinician for personal guidance.

Easy Read

Imagine you are looking at a beautiful house. The lawn is a perfect green. The windows are clean and shiny. From the street, the house looks brand new. But behind the walls, there is a “ghost in the machine.” The water pipes are old and rusty. The electric wires are fraying and sparking. You cannot see these problems just by looking at the outside. One day, a pipe bursts or a fire starts. Everyone is shocked. They say, “But the house looked so good!”

This is exactly what happens to many people and their hearts. Many people go to the doctor and get a “clean bill of health.” They feel fine. They pass their basic tests. Their doctor tells them everything looks “good.” Then, suddenly, they have a heart attack. This happens because our old tests are like looking at the house from the street. They miss the “rusty pipes” inside the heart walls.

Today, we are at the start of a massive change. It is a “paradigm shift.” This means we are changing the way we do things from the ground up. Instead of waiting for a “fire” to start in the heart, we are using Artificial Intelligence (AI) to find the danger years before it causes trouble. We are moving from a world where we react to pain to a world where we can see the truth clearly.

The “Hidden” Danger: Most Heart Attacks Don’t Come from Total Blockages

Most of us think a heart attack is like a clogged kitchen sink. We think a pipe gets filled with “gunk” until no blood can get through. In the medical world, this narrowing is called “stenosis.” Doctors used to think that if a pipe was 90% blocked, you were at high risk. If it was only 20% blocked, they thought you were safe.

But here is the scary secret: most heart attacks do not happen in the pipes that are mostly blocked. They happen in pipes that look mostly open.

Think of a “blister” inside the wall of a pipe. On the outside, the pipe looks fine. Blood flows through it easily. But inside the wall, that blister is full of soft, fatty “grease.” This grease is very unstable. If that blister pops, it creates a sudden clot. That clot is what stops the blood and causes the heart attack. Because the pipe was not “clogged” before the blister popped, a regular test would say the person is perfectly fine.

The numbers tell a story that every person should know:

“Autopsy and angiographic studies demonstrate that approximately 70–75% of myocardial infarctions occur in vessels with less than 50% stenosis prior to the index event.”

This means that out of every 10 people who have a heart attack, 7 or 8 of them would have passed a test that only looks for big clogs. Their heart pipes were more than half open right before the disaster. This is why “looking good” on a standard test is not enough.

Why Standard Tests Can Be “Blind”

For a long time, doctors used “stress tests.” You might have done one of these. You walk on a treadmill while a machine watches your heart. If your heart pipes are 90% blocked, your heart won’t get enough blood when you run, and the test will show it. But if you have those “greasy blisters” that are only taking up 30% of the pipe, the blood still flows fine while you run. The stress test will say you are “normal,” even though you have a hidden danger ready to pop.

Another common test is a Calcium Score. This test looks for hard calcium in your heart pipes. Calcium is like a “scar.” It shows that there was damage in the past that has now turned hard like bone. While knowing your calcium score is helpful, it is like looking at a scar on your knee from ten years ago. It tells you that you were hurt, but it doesn’t tell you if you have a fresh, bleeding wound right now.

In the heart, “grease” (non-calcified plaque) is the fresh danger. A person can have a Calcium Score of zero and still have a heart full of soft, dangerous grease. Here is how the new AI way compares to the old ways:

Feature of the Heart	Traditional Tests (Like Calcium Scoring)	The New AI Way (AI-QCT)
Hard (Calcified) Scars	Very easy to see	Very easy to see
Soft “Greasy” Blisters	Cannot see it at all	Very clear and easy to see
High-Risk Grease	Blind to this danger	Finds it very easily
Total Amount of Plaque	Only a rough guess	Precise measurement (mm³)
Risk Prediction	General guess	Highly accurate and personal

AI-QCT: Your Heart’s New “Super-Vision”

To fix this, scientists made a tool called AI-QCT. That is a big name, but think of it as a “Digital Magnifying Glass.”

When a human doctor looks at a heart scan, they are looking at pictures with their eyes. Even the best doctors can miss tiny things. AI-QCT uses Artificial Intelligence to look at the pictures much more closely. The AI does not just look at the whole picture; it looks at “voxels.” A voxel is like a 3D pixel. Imagine a tiny, tiny cube. The AI looks at every single tiny cube in your heart pipes.

The AI uses “deep learning.” This means the computer has looked at thousands and thousands of other heart scans. It has learned to see patterns that the human eye simply cannot perceive. It can tell the difference between “safe” hard calcium and “dangerous” soft grease by looking at the shadows and colors in the scan data. It is non-invasive, meaning no one has to put tubes or wires inside you to see this. The AI does the “seeing” using the data from a regular CT scan.

Turning Data Into a Roadmap: The Power of Measurement

The biggest power of AI is that it can “quantify” things. This means it gives us a real number. Instead of a doctor saying, “You have a little bit of plaque,” the AI can say, “You have exactly 154 cubic millimeters (mm³) of plaque.”

Why does this matter? Because you cannot fix what you cannot measure.

When a doctor knows exactly how much “grease” is in your heart, they can create a better plan. This has been proven in big medical studies:

The CONFIRM2 Registry: This study looked at thousands of people. It showed that when AI measured the plaque, doctors became much better at predicting the future. Their ability to predict a heart problem (called the AUC) went from a 0.62 to a much higher 0.75.
The PROMISE Study: In this study, the AI looked at scans and changed the results. For 41% of the narrowings (stenoses), the AI “reclassified” them. This means the AI found that the old way of looking at things was wrong for 4 out of every 10 people.
The CREDENCE Trial: This showed that the AI was just as good as expensive, invasive tests where doctors put tubes into the heart.
The CERTAIN Study: This study found that using AI made doctors much more “certain” about what to do. It helped them give the right medicine and avoid tests that were not needed.

This leads to something called “treat-to-target.” It is like a GPS for your heart. If you have 154 mm³ of plaque, you start a plan with diet, exercise, and medicine. A year later, you get another scan. If the AI says you now have 110 mm³, you know your plan is working! You can actually see the “grease” shrinking. This gives patients a huge sense of relief and hope.

The Next Level: Photon-Counting CT

Technology is taking another giant leap with something called “Photon-Counting CT” (PCCT). In the past, CT scanners were like old box TVs. The pictures were a little fuzzy. One big problem was “calcium blooming.” This is like a blinding “glare” from a flashlight. If you had a hard piece of calcium, it would glow so bright in the picture that it would hide the soft grease sitting right next to it.

The new Photon-Counting machines turn light directly into electricity. This makes the picture much clearer. It is like going from an old TV to a brand-new high-definition screen.

This new hardware solves many problems:

No More Glare: It stops the “calcium blooming.” The AI can now see past the hard “scars” to find the hidden grease.
Clearer Pictures: It removes “noise” or fuzziness from the image.
Better for More People: In the past, if a person had a very fast heart rate or weighed more, the pictures were too blurry to use. These new machines can see clearly through almost anything.

Conclusion: A Future Where Heart Attacks are Optional

We are moving into a new era. In the past, heart care was “episodic.” This means you only checked on your heart once in a while, or only when you felt a pain in your chest. That is like checking your GPS only after you are already lost.

Now, we are moving to “longitudinal” monitoring. This means we track the disease over time, like watching a map as you drive. We can see the very first signs of rust in the pipes years before they burst. We are facing a big challenge as a world:

“As cardiovascular disease remains the leading cause of mortality worldwide, with annual deaths projected to exceed 20 million by 2030, improved methods for identifying high-risk coronary atherosclerosis before clinical events occur are increasingly necessary.”

With AI and new scanners, many of those deaths could be stopped. We no longer have to guess if someone is healthy. We can see the truth. We can see if the medicine is working. We can see the future.

If you could see the future of your heart today, would you change how you live tomorrow? With AI, we finally have the power to see that future—and the power to change it for the better.

Medical Disclaimer: This article is for education only and is not medical advice. Always consult your clinician for personal guidance. Curing Heart Disease, LLC is a registered business name and does not imply the diagnosis, treatment, cure, or prevention of any disease. Information is educational only and not medical advice. Use of this information is at your own risk. Always seek the advice of your physician with any questions regarding a medical condition.

Deep Dive

The Technological Renaissance in Preventive Cardiology – Artificial Intelligence, Quantitative Coronary Tomography

Introduction

Cardiovascular medicine is undergoing a substantive paradigm shift, moving from a predominantly reactive, symptom-driven model toward a preventive framework grounded in early detection and individualized risk assessment. At the center of this transition is the integration of artificial intelligence (AI) with coronary computed tomography angiography (CCTA), particularly through the development of atherosclerosis imaging–quantitative computed tomography (AI-QCT). This approach addresses a long-standing limitation in cardiology: the inability of traditional diagnostic tools to reliably detect non-obstructive, lipid-rich coronary plaque, despite such lesions being responsible for the majority of acute coronary syndromes and sudden cardiac death events (1).

The clinical relevance of this limitation is substantial. Epidemiologic and pathologic studies consistently demonstrate that most myocardial infarctions arise from plaques that were not flow-limiting prior to rupture (2). As cardiovascular disease remains the leading cause of mortality worldwide, with annual deaths projected to exceed 20 million by 2030, improved methods for identifying high-risk coronary atherosclerosis before clinical events occur are increasingly necessary (3).

Evolution of Cardiac Risk Stratification and the Biology of Atherosclerosis

Traditional cardiovascular risk stratification relies on indirect markers such as serum lipid levels, blood pressure, glycemic control, smoking status, and demographic variables incorporated into population-based risk calculators. While these models have proven useful at a population level, they often lack precision when applied to individual patients, particularly those with apparently “normal” risk factor profiles who nonetheless harbor significant subclinical disease (4).

Atherosclerosis is a chronic inflammatory disease of the arterial wall rather than a disorder defined solely by luminal obstruction. Plaque develops within the intima and consists of varying proportions of lipid, fibrous tissue, inflammatory cells, and calcium. Conventional diagnostic tests—including exercise stress testing, electrocardiography, and invasive coronary angiography—primarily detect disease once it produces hemodynamically significant stenosis, typically defined as luminal narrowing of 70% or greater (5).

Insight 1: Autopsy and angiographic studies demonstrate that approximately 70–75% of myocardial infarctions occur in vessels with less than 50% stenosis prior to the index event, indicating that most patients who experience acute coronary syndromes would not have been identified as high risk by standard stress testing alone (2).

Insight 2: Coronary artery calcium scoring (CACS) was developed to improve detection of subclinical disease by identifying calcified plaque. However, CACS does not detect non-calcified plaque, and a calcium score of zero does not exclude the presence of lipid-rich, rupture-prone lesions (6).

Insight 3: AI-QCT enables non-invasive quantification of total coronary plaque burden, including low-density non-calcified plaque, which has been shown to carry a higher association with future cardiovascular events than stenosis severity alone (7).

Plaque Characteristic	Visibility (CACS)	Visibility (Standard CCTA)	Visibility (AI-QCT)	Clinical Risk Profile
Calcified plaque	High	High	High	Generally stable; marker of chronic disease
Non-calcified plaque	None	Qualitative / limited	Quantitative / high	Elevated rupture risk
Low-density plaque	None	Variable	High	Strong association with ACS
Total plaque volume	None	Indirect estimate	Precise (mm³)	Strong predictor of future events

Technical Architecture of AI-Enabled Coronary Analysis

AI-QCT platforms perform voxel-level analysis of the coronary tree rather than relying on visual interpretation alone. These systems employ deep-learning architectures—including convolutional neural networks (CNNs), three-dimensional U-Net segmentation models, and VGG-derived classifiers—trained on large, curated datasets that link imaging features with invasive validation and long-term clinical outcomes (8).

Insight 4: AI-QCT begins with acquisition of high-resolution CCTA. Contemporary multi-detector CT systems, including 64- and 640-slice scanners, provide the temporal and spatial resolution necessary to minimize motion artifact and enable accurate segmentation of coronary anatomy (5).

Insight 5: Automated algorithms identify the coronary lumen and vessel wall and classify plaque components according to Hounsfield unit attenuation values, allowing differentiation of lipid-rich, fibrous, and calcified tissue (9).

Insight 6: AI-derived ischemia indices integrate plaque morphology, lesion length, vessel remodeling, and luminal geometry to estimate flow limitation, providing a non-invasive correlate of invasive fractional flow reserve (FFR) (10).

Clinical Validation and Peer-Reviewed Evidence

AI-QCT has been evaluated in multiple prospective trials, registries, and comparative studies published in leading cardiovascular and imaging journals, including Journal of the American College of Cardiology, Circulation: Cardiovascular Imaging, and European Heart Journal – Cardiovascular Imaging (11).

Landmark Trials and Registries

Insight 7: The CREDENCE trial demonstrated close agreement between AI-assisted CCTA analysis and invasive quantitative coronary angiography and FFR, supporting the diagnostic accuracy of AI-QCT for identifying hemodynamically significant disease (12).

Insight 8: The CONFIRM2 registry, encompassing tens of thousands of patients across multiple countries, showed that AI-quantified plaque features identify a wide gradient of cardiovascular risk among patients with non-obstructive coronary artery disease (7).

Insight 9: The CERTAIN study demonstrated that AI-QCT significantly improved diagnostic certainty compared with standard interpretation, resulting in more appropriate medical therapy and fewer unnecessary downstream tests (1).

Study	N	Key Finding	P-value	Clinical Implication
CONFIRM2	6,550	AUC for MACE improved from 0.62 to 0.75	<0.001	Improved prognostic accuracy
CREDENCE	513	High concordance with invasive FFR	<0.01	Viable non-invasive ischemia assessment
PACIFIC-1	208	AI exceeded expert readers	<0.05	Reduced inter-observer variability
PROMISE (subset)	4,347	41% stenoses reclassified	—	Reduced false positives

Preventive Cardiology Implementation and Longitudinal Disease Monitoring

Integration of AI-QCT into preventive cardiology workflows shifts the clinical focus from episodic evaluation toward longitudinal monitoring of atherosclerotic disease.

Insight 10: Quantification of total plaque burden enables objective assessment of disease progression or regression over time, facilitating a treat-to-target approach guided by serial imaging (7).

Insight 11: AI-based comparison tools permit evaluation of changes in plaque composition, including stabilization or regression of lipid-rich plaque in response to medical therapy (13).

Hardware Advances: Photon-Counting Computed Tomography

The performance of AI-QCT is dependent on the quality of input imaging data, which continues to improve with advances in CT hardware.

Insight 12: Photon-counting CT (PCCT) systems directly convert X-ray photons into electrical signals, reducing electronic noise and calcium blooming artifacts compared with conventional energy-integrating detectors (14).

Insight 13: PCCT provides higher spatial resolution with lower radiation and contrast dose, expanding eligibility for coronary CT imaging to patients with high heart rates, elevated body mass index, or extensive coronary calcification (15).

Economic and Health System Implications

The adoption of AI-enabled cardiac imaging aligns with broader healthcare trends toward value-based care and prevention.

Insight 14: Market analyses project rapid growth of AI applications in cardiology, driven by improved diagnostic efficiency and potential reductions in downstream costs associated with acute coronary events (16).

Insight 15: Early identification of high-risk plaque phenotypes may reduce myocardial infarction rates and associated healthcare expenditures by enabling earlier and more targeted intervention (17).

Conclusions and Future Directions

Preventive cardiology is increasingly transitioning toward a biologically informed model that emphasizes plaque burden and composition rather than stenosis severity alone. AI-QCT provides a reproducible, quantitative framework for assessing coronary atherosclerosis before clinical events occur.

Insight 16: Future developments are likely to include integration of agentic AI systems, longitudinal digital heart models, and multimodal data streams incorporating genomic and metabolic information (18).

Insight 17: As AI assumes a greater role in image interpretation and quantification, clinicians may increasingly focus on higher-level clinical decision-making, risk communication, and individualized therapy optimization (19).

References

Nurmohamed NS, Cole JH, Budoff MJ, et al. Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study. Eur Heart J Cardiovasc Imaging. 2024;25(6):857-866. doi:10.1093/ehjci/jeae029
Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657-671. doi:10.1161/01.cir.92.3.657
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025;86(22):2167-2243. doi:10.1016/j.jacc.2025.08.015
Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121(15):1768-1777. doi:10.1161/CIRCULATIONAHA.109.849166
Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-1300. doi:10.1056/NEJMoa1415516
Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. J Am Coll Cardiol. 2018;72(4):434-447. doi:10.1016/j.jacc.2018.05.027
Feuchtner GM, Lacaita PG, Bax JJ, et al. AI-Quantitative CT Coronary Plaque Features Associate With a Higher Relative Risk in Women: CONFIRM2 Registry. Circ Cardiovasc Imaging. 2025;18(6):e018235. doi:10.1161/CIRCIMAGING.125.018235
Oikonomou EK, Khera R. Machine learning in precision diabetes care and cardiovascular risk prediction. Cardiovasc Diabetol. 2023;22(1):259. Published 2023 Sep 25. doi:10.1186/s12933-023-01985-3
Koo BK, Yang S, Jung JW, et al. Artificial Intelligence-Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome. JACC Cardiovasc Imaging. 2024;17(9):1062-1076. doi:10.1016/j.jcmg.2024.03.015
Nørgaard BL, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol. 2014;63(12):1145-1155. doi:10.1016/j.jacc.2013.11.043
Beerkens FJ, Tang GHL, Kini AS, et al. Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2025;85(9):944-964. doi:10.1016/j.jacc.2024.11.051
Griffin WF, Choi AD, Riess JS, et al. AI Evaluation of Stenosis on Coronary CTA, Comparison With Quantitative Coronary Angiography and Fractional Flow Reserve: A CREDENCE Trial Substudy. JACC Cardiovasc Imaging. 2023;16(2):193-205. doi:10.1016/j.jcmg.2021.10.020
Zaman S, Wasfy JH, Kapil V, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025;405(10486):1264-1312. doi:10.1016/S0140-6736(25)00055-8
Willemink MJ, Persson M, Pourmorteza A, Pelc NJ, Fleischmann D. Photon-counting CT: Technical Principles and Clinical Prospects. Radiology. 2018;289(2):293-312. doi:10.1148/radiol.2018172656
Schiebler ML, Jinzaki M, Yanagawa M, et al. Future Applications of Cardiothoracic CT. Radiology. 2025;315(3):e240085. doi:10.1148/radiol.240085
Windecker S, Gilard M, Achenbach S, et al. Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table. Eur Heart J. 2024;45(13):1104-1115. doi:10.1093/eurheartj/ehae069
Undas A, Musiał J, Ząbczyk M. Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances. Rheumatol Int. 2025;45(12):279. Published 2025 Nov 29. doi:10.1007/s00296-025-06050-8
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7
Shetty NS, Gaonkar M, Pampana A, et al. Association of Pathogenic/Likely Pathogenic Inherited Cardiomyopathy Variants With Heart Failure: A TOPMed Multiancestry Analysis. Mayo Clin Proc. 2025;100(11):1948-1955. doi:10.1016/j.mayocp.2025.01.021

Transparency Note: This blog post was created with assistance from AI tools. The final content has been carefully reviewed and edited by the author, who is responsible for its accuracy. The information provided is for educational purposes only and does not constitute medical advice.

CuringHeartDisease

Always searching for a cure
Peter Megdal, PhD

The Future of Heart Disease Management

How to Use This Article

Medical disclaimer: This article is for education only and is not medical advice. Always consult your clinician for personal guidance.

Easy Read